Photo from wikipedia
It is unarguable that residual tumor volume after primary cytoreductive surgery is the best prognostic factor in clinical course of epithelial ovarian cancer [1]. Nowadays, residual tumor volume does not… Click to show full abstract
It is unarguable that residual tumor volume after primary cytoreductive surgery is the best prognostic factor in clinical course of epithelial ovarian cancer [1]. Nowadays, residual tumor volume does not only predict patients' prognosis but also guides adjuvant treatment strategy including application of targeting drugs. Thus, a growing number of current clinical trials are selecting or stratifying their subjects according to the most significant predictor of prognosis, residual tumor volume. Does this best prognostic factor have a weakness? Yes. It is subjective.
Journal Title: Journal of Gynecologic Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!